Summit Therapeutics (SMMT) Change in Accured Expenses (2019 - 2026)
Summit Therapeutics' (SMMT) quarterly Change in Accured Expenses came in at $20.7 million in Q2 2026, up 47.7% YoY from $14.0 million in Q2 2025, and up 69.72% on a QoQ basis from $12.2 million in Q1 2026.
Summit Therapeutics (SMMT) Change in Accured Expenses (2019 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 8 years of Change in Accured Expenses data on file, last reported at $20.7 million in Q2 2026.
- Quarterly Change in Accured Expenses rose 47.7% year-over-year to $20.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $39.4 million (up 169.63% YoY) and the FY2025 annual result came in at $12.9 million, up 8.85% from the prior year.
- Change in Accured Expenses improved to $20.7 million in Q2 2026, from $12.2 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $20.7 million in Q2 2026 to a low of -$7.6 million in Q1 2025.
- A 5-year average of $3.3 million and a median of $1.6 million in 2024 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 15388.57% in 2023, down 1079.45% in 2023.
- Tracing SMMT's Change in Accured Expenses over 5 years: stood at -$35000.0 in 2022, then soared by 15388.57% to $5.4 million in 2023, then sank by 57.41% to $2.3 million in 2024, then jumped by 142.78% to $5.5 million in 2025, then jumped by 274.79% to $20.7 million in 2026.
- The last three Change in Accured Expenses figures came in at $20.7 million (Q2 2026), $12.2 million (Q1 2026), and $5.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 20.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.74 Mn |
| Jun 30, 2026 | 20.74 Mn |
| Mar 31, 2026 | 12.22 Mn |
| Mar 31, 2026 | 12.22 Mn |
| Dec 31, 2025 | 5.53 Mn |
| Dec 31, 2025 | 5.53 Mn |
| Sep 30, 2025 | 945,000.00 |
| Sep 30, 2025 | 945,000.00 |
| Jun 30, 2025 | 14.04 Mn |
| Jun 30, 2025 | 14.04 Mn |
| Mar 31, 2025 | -7.59 Mn |
| Mar 31, 2025 | -7.59 Mn |
| Dec 31, 2024 | 2.28 Mn |
| Dec 31, 2024 | 2.28 Mn |
| Sep 30, 2024 | 5.89 Mn |
| Sep 30, 2024 | 5.89 Mn |
| Jun 30, 2024 | 5.93 Mn |
| Jun 30, 2024 | 5.93 Mn |
| Mar 31, 2024 | -2.23 Mn |
| Mar 31, 2024 | -2.23 Mn |